Stryker Corporation $SYK Shares Purchased by Procyon Advisors LLC

Procyon Advisors LLC increased its stake in shares of Stryker Corporation (NYSE:SYK) by 99.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,138 shares of the medical technology company’s stock after buying an additional 2,564 shares during the quarter. Procyon Advisors LLC’s holdings in Stryker were worth $1,806,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Davis R M Inc. grew its stake in shares of Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after buying an additional 2,512 shares during the period. Terra Alpha Investments LLC purchased a new stake in shares of Stryker during the 3rd quarter valued at approximately $1,216,000. Kepler Cheuvreux Suisse SA purchased a new stake in shares of Stryker during the 3rd quarter valued at approximately $27,952,000. Diversified Trust Co lifted its holdings in Stryker by 45.6% in the third quarter. Diversified Trust Co now owns 12,445 shares of the medical technology company’s stock valued at $4,601,000 after acquiring an additional 3,899 shares during the last quarter. Finally, SVB Wealth LLC purchased a new position in Stryker in the second quarter worth approximately $4,785,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 1.1%

Shares of NYSE SYK opened at $335.96 on Monday. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $128.57 billion, a PE ratio of 39.99, a PEG ratio of 1.96 and a beta of 0.85. Stryker Corporation has a twelve month low of $328.23 and a twelve month high of $404.87. The stock has a fifty day simple moving average of $363.25 and a 200-day simple moving average of $365.72.

Stryker (NYSE:SYK) last released its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.Stryker’s revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the company posted $4.01 EPS. On average, equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s payout ratio is 41.90%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. The Goldman Sachs Group set a $399.00 target price on Stryker in a research note on Friday, January 9th. Citigroup reaffirmed a “market outperform” rating on shares of Stryker in a research note on Friday, January 30th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a report on Monday, December 22nd. Robert W. Baird set a $437.00 price objective on Stryker in a research report on Friday, January 30th. Finally, Truist Financial decreased their target price on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research report on Thursday, December 18th. Fourteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average target price of $427.50.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.